
Work Here?
Neogen develops and markets test kits and services to detect a range of safety issues in the food and animal supply chain. Its products help identify foodborne bacteria, natural toxins, and drug residues in animals, and the company divides its offerings into two segments: Food Safety and Animal Safety. Products are delivered as test kits and related services that enable customers to screen and verify safety at various stages from farm to fork. The firm differentiates itself through its scale and geographic reach, a consequence of the 2022 merger with 3M’s food safety business that nearly doubled its size and created a global leader in food safety by expanding product lines and geographic footprint. Neogen’s goal is to ensure the safety of the world’s food supply by providing comprehensive tools and services that detect contaminants and residues across the food and animal industries.
Industries
Food & Agriculture
Biotechnology
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Lansing, Michigan
Founded
1982
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$550M
Above
Industry Average
Funded Over
1 Rounds
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Performance Bonus
Profit Sharing
Employee Stock Purchase Plan
Relocation Assistance
Employee Referral Bonus
Student Loan Assistance
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Pet Insurance
Bereavement Leave
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Wellness Program
Mental Health Support
Gym Membership
Commuter Benefits
Meal Benefits
Phone/Internet Stipend
Home Office Stipend
Legal Services
Employee Discounts
Company Social Events
UQ research sharpens new genetic test to breed hornless cattle. 30 April 2026 Australian cattle producers can more accurately determine whether animals in their herd will grow horns, thanks to a new genetic test developed using University of Queensland research. UQ's commercialisation company UniQuest licensed the research to Neogen Corporation, which unveiled its new genetic test at the Australian Brahman Breeders' Association annual conference in Airlie Beach this week. Queensland Alliance for Agriculture and Food Innovation Associate Professor Elizabeth Ross said her team identified a previously undetected variant of the polled, or hornless, gene in Australian cattle. "The Guarani poll test is a specialised genetic test used in cattle breeding to identify the presence of a specific hornless genetic variant in Bos indicus breeds, such as the Australian Brahman," Dr Ross said. "This is the first test able to detect a Guarani poll mutation, which is one of 4 gene variants associated with hornless cattle including Celtic, Friesian and Mongolian." Dr Ross said existing commercial genetic tests detected only 2 of the 4 known hornless or polled mutations. "Cattle producers are increasingly using DNA tests to breed horns out of their cattle herds because polled animals are safer and allow for more welfare-friendly management," Dr Ross said. "University of Queensland know the Pg allele, the variant gene causing horns not to grow on some animals, is out there in the Australian Brahman population because University of Queensland has found it directly in 3 of the 4 herds University of Queensland studied. "This test will finally give producers with hornless cattle more accurate genetic test results and allow them to purposely breed hornless calves." Neogen strategic beef accounts manager Hannah Bourke said it was pleased to partner with UniQuest to deliver the new Guarani Poll DNA test to the Australian market. "We are proud to be able to deliver commercially relevant solutions to industry," Ms Bourke said. UniQuest CEO Dr Dean Moss said it was exciting to see UQ research drive meaningful results for Australian producers. "This test will give Australian cattle producers confidence in their breeding decisions and it's fantastic UQ research has played a vital role in that," Dr Moss said. The test will be available to Australian producers from May 2026. The Poll Guarani allele was originally discovered by Utsunomiya et al in 2019 in cattle in Brazil, and named as Guarani (PG) after the aquifer beneath its assumed region of origin. Researchers at UQ have discovered a previously undetected causal variant of the polled or hornless gene in Australian cattle. 1 April 2026 An analysis of data from northern Australian cattle has identified key regions of the genome that influence traits like fertility, growth and body condition, sometimes all at the same time. 10 March 2026 Media contact. Get the latest from its newsroom.
Neogen Corporation reported fiscal third-quarter 2026 results with revenue of $211.2 million, down from $221 million year-on-year, and a net loss of $17 million. The company modestly raised full-year 2026 revenue guidance to approximately $857 million to $860 million. Neogen is reshaping its portfolio through strategic moves, including appointing Jennifer Evans Stacey as Chief Legal & Compliance Officer and agreeing to sell its Genomics business to Zoetis for $160 million. The sale will tighten focus on core Food Safety and Animal Safety segments whilst providing funds for debt reduction. Despite the improved guidance and portfolio streamlining efforts, execution risks remain around integration, supply constraints in Animal Safety, and potential stranded costs following divestitures. Analysts project revenue of $869 million and earnings of $113.7 million by 2029.
Neogen Corporation reported Q3 2026 results with Food Safety segment achieving 4% core growth and adjusted EBITDA margins expanding to 22.8%. However, Animal Safety revenue declined 8.7% on a core basis due to third-party supplier transitions, raw material shortages and documentation issues. The company is transitioning from regional operations to a unified global selling framework whilst implementing AI-enabled logistics to reduce manual processes. The Petrifilm manufacturing transition remains on schedule for November 2026, with all production equipment validated. Management expects significant free cash flow improvement in fiscal 2027 as capital expenditures subside. The genomics business divestiture, expected to close in Q2 fiscal 2027, should reduce net debt to adjusted EBITDA below 3x by year-end 2026. Global logistics disruptions are driving high single-digit to low double-digit increases in freight costs.
Neogen, a life sciences company, reported first-quarter results for calendar year 2026 that exceeded revenue expectations, though sales declined 4.4% year on year to $211.2 million. The company's non-GAAP profit of $0.09 per share beat analyst estimates by 68.8%. Neogen raised its full-year revenue guidance to $858.5 million at the midpoint, 0.9% above analyst expectations. Adjusted EBITDA reached $48.2 million with a 22.8% margin, beating estimates by 18.4%. Free cash flow improved to $11.07 million from negative $13.51 million in the prior-year quarter. Despite the quarterly beat, Neogen's recent performance shows annualised revenue declines of 3.2% over the past two years. Analysts project revenue will decline 1.2% over the next 12 months.
Neogen Corporation reported third quarter fiscal year 2026 revenue of $211.2 million, down 4.4% year-over-year, though core revenue increased 0.1%. The food safety solutions company raised its full-year revenue guidance to $857 million to $860 million, up from previous guidance of $845 million to $855 million. The Food Safety segment grew 2.6% to $156.7 million, with core growth of 4.0%. However, Animal Safety revenue fell 20.1% to $54.5 million due to third-party supplier issues affecting production. Net loss was $17.0 million, or $0.08 per diluted share, compared to a $10.9 million loss in the prior year. Adjusted EBITDA reached $48.2 million with a 22.8% margin, up from 22.0% previously. Neogen is transitioning Petrifilm manufacturing and has agreed to sell its global Genomics business to Zoetis for $160 million.
Find jobs on Simplify and start your career today
Industries
Food & Agriculture
Biotechnology
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Lansing, Michigan
Founded
1982
Find jobs on Simplify and start your career today